Core Insights - The article discusses the performance of international stocks and highlights the impact of the weakening US dollar and trade policies on global markets [2][3] Group 1: Market Trends - The weakness in the US dollar is identified as a major catalyst for the performance of global stocks, with the first half of 2025 being the worst for dollar weakness since the early 1970s [2] - Oversaturation in the "Magnificent Seven" has led investors to explore international markets, recognizing that technology growth is not limited to the US [2] - Trade and tariff wars have prompted international markets to adopt growth-friendly policies, resulting in increased trade deals and reduced regulatory barriers in regions like Europe, China, and India [3] Group 2: Investment Opportunities - The article presents a list of 10 high-growth international stocks, emphasizing the potential for attractive investment opportunities outside the US [4] - The methodology for selecting these stocks involved using stock screeners and hedge fund databases to identify companies with over 25% revenue growth over the past three years [6] Group 3: Company Highlights - Genmab A/S (NASDAQ:GMAB) reported a significant increase in net sales of DARZALEX, reaching $14.351 billion in 2025, up from $11.670 billion in 2024, with over half of the sales coming from the US [9][10] - Genmab's royalty revenue for the first nine months of 2025 was $2.219 billion, a 23% increase from $1.802 billion in the same period of 2024, attributed to higher sales of DARZALEX and Kesimpta [11] - BeOne Medicines AG (NASDAQ:ONC) received a Buy rating with a price target increase following the first-in-world approval of Sonrotoclax in China for treating difficult blood cancers, with a 52.4% overall response rate in MCL studies [14][15][16]